항바이오필름제 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of anti-biofilm agents Market

The global anti-biofilm agents market is witnessing steady growth, driven by the rising prevalence of acute and chronic wounds and the increasing burden of biofilm-associated infections. According to Fortune Business Insights, the global anti-biofilm agents market was valued at USD 1.5 billion in 2025. The market is projected to grow from USD 1.64 billion in 2026 to USD 3.21 billion by 2034, exhibiting a CAGR of 8.79% during the forecast period. North America dominated the market with a share of 36.49% in 2025, supported by advanced wound care infrastructure and higher awareness of biofilm management.

Anti-biofilm agents are products designed to prevent, disrupt, or manage biofilms, which are structured communities of microorganisms embedded within a self-produced matrix. Biofilms are commonly found in chronic wounds and significantly delay healing by increasing resistance to antibiotics and immune responses. According to data published by MDPI in 2024, biofilm formation occurs in approximately 60% of chronic wounds and 10% of acute wounds, highlighting the growing clinical need for effective anti-biofilm solutions.

Market Dynamics

Market Drivers

The increasing prevalence of acute and chronic wounds is a primary driver of market growth. Conditions such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and burn injuries are associated with a high risk of biofilm formation. For instance, data published by the National Center for Biotechnology Information in 2023 reported that the global prevalence of diabetic foot ulcers is around 6.3%. Additionally, hospital-acquired pressure ulcers remain a concern, with studies estimating an incidence of 8.7% among hospitalized patients in the U.K. These trends are driving the demand for advanced wound care and anti-biofilm products.

Market Restraints

Limited diagnosis and treatment rates in developing countries are restraining market growth. Delayed referrals, lack of clinical expertise, insufficient awareness, and absence of standardized guidelines often result in delayed diagnosis of chronic wounds. Studies published in 2023 reported delays ranging from 15 to 126 days from symptom onset to specialist assessment in patients with diabetic foot ulcers. These delays reduce timely adoption of anti-biofilm agents, particularly in emerging markets such as India, China, and Brazil.

Market Opportunities

Growing research and development activities among key players present significant growth opportunities. Companies are investing heavily in clinical trials and product innovation to introduce advanced dressings, gels, and powders with enhanced anti-biofilm properties. For example, in May 2024, Convatec Inc. reported positive clinical outcomes for its AQUACEL Ag+ Extra dressing in managing venous leg ulcers. Increasing government initiatives to improve wound care awareness further support market expansion.

Market Challenges

Limited adherence to biofilm prevention and management guidelines remains a challenge, particularly in developing regions. Low awareness among healthcare providers and patients leads to improper wound care practices, increasing the prevalence of biofilms. Additionally, the high cost of advanced anti-biofilm products restricts their adoption in cost-sensitive healthcare systems.

Anti-Biofilm Agents Market Trends

The introduction of novel anti-biofilm products is a key market trend. Researchers are increasingly exploring nanotechnology, nano-drug delivery systems, and antimicrobial nanoparticles such as silver and zinc oxide to improve biofilm penetration and disruption. Clinical studies evaluating these advanced technologies are expected to enhance product efficacy and boost demand during the forecast period.

Segmentation Analysis

By product, dressings dominated the market, accounting for 67.86% share in 2026, driven by their effectiveness in preventing bacterial contamination and managing biofilms.

By molecule, the silver segment led the market with a 47.62% share in 2026, owing to its broad-spectrum antimicrobial activity.

By wound type, chronic wounds accounted for 68.15% of the market in 2026, supported by the high prevalence of diabetic foot ulcers and pressure ulcers.

By end user, hospitals dominated with a 43.12% share in 2026, reflecting higher hospitalization rates and access to advanced wound care solutions.

Regional Outlook

North America led the market with a valuation of USD 0.55 billion in 2025 and USD 0.59 billion in 2026, supported by strong healthcare expenditure and product innovation.

Europe is expected to grow steadily due to established healthcare systems and rising awareness.

Asia Pacific is projected to register the fastest growth, driven by increasing wound prevalence and expanding research activities.

Latin America and the Middle East & Africa are expected to grow due to rising disposable incomes, healthcare infrastructure development, and increasing awareness of wound management.

Competitive Landscape

The market is moderately consolidated, with key players such as Smith+Nephew, Convatec Inc., and Coloplast A/S holding significant shares. These companies focus on product launches, clinical research, collaborations, and geographic expansion to strengthen their market position. Other notable players include Molnlycke AB, URGO MEDICAL, Solventum, and Imbed Biosciences.

Conclusion

The global anti-biofilm agents market is set for consistent growth over the forecast period, driven by the rising prevalence of chronic and acute wounds, increasing awareness of biofilm-associated complications, and continuous advancements in wound care technologies. With the market valued at USD 1.5 billion in 2025, projected to grow to USD 1.64 billion in 2026 and reach USD 3.21 billion by 2034, sustained R&D investments, innovation in antimicrobial technologies, and expanding healthcare infrastructure are expected to support long-term market expansion despite challenges related to cost, awareness, and guideline adherence.

Segmentation

By Product

• Dressings
• Ointments / Gels
• Powders

By Molecule

• Silver
• Iodine
• Honey
• Others

By Wound Type

• Chronic Wounds
• Acute Wounds

By End User

• Hospitals
• Wound Clinics
• Home Care Settings
• Others

By Region

• North America (By Product, By Molecule, By Wound Type, By End User, and By Country)
  • U.S.
  • Canada
• Europe (By Product, By Molecule, By Wound Type, By End User, and By Country)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific (By Product, By Molecule, By Wound Type, By End User, and By Country)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, By Molecule, By Wound Type, By End User, and By Country)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, By Molecule, By Wound Type, By End User, and By Country)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, Key Countries, 2025/2025
• 4.2. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.3. Detailed Product Offerings: Anti-biofilm Agents, Key Players

5. Global Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Dressings
  • 5.1.2. Ointments / Gels
  • 5.1.3. Powders
• 5.2. Market Analysis, Insights and Forecast - By Molecule
  • 5.2.1. Silver
  • 5.2.2. Iodine
  • 5.2.3. Honey
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Wound Type
  • 5.3.1. Chronic Wounds
  • 5.3.2. Acute Wounds
• 5.4. Market Analysis, Insights and Forecast - By End-user
  • 5.4.1. Hospitals
  • 5.4.2. Wound Clinics
  • 5.4.3. Homecare Settings
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Dressings
  • 6.1.2. Ointments / Gels
  • 6.1.3. Powders
• 6.2. Market Analysis, Insights and Forecast - By Molecule
  • 6.2.1. Silver
  • 6.2.2. Iodine
  • 6.2.3. Honey
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Wound Type
  • 6.3.1. Chronic Wounds
  • 6.3.2. Acute Wounds
• 6.4. Market Analysis, Insights and Forecast - By End-user
  • 6.4.1. Hospitals
  • 6.4.2. Wound Clinics
  • 6.4.3. Homecare Settings
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Dressings
  • 7.1.2. Ointments / Gels
  • 7.1.3. Powders
• 7.2. Market Analysis, Insights and Forecast - By Molecule
  • 7.2.1. Silver
  • 7.2.2. Iodine
  • 7.2.3. Honey
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Wound Type
  • 7.3.1. Chronic Wounds
  • 7.3.2. Acute Wounds
• 7.4. Market Analysis, Insights and Forecast - By End-user
  • 7.4.1. Hospitals
  • 7.4.2. Wound Clinics
  • 7.4.3. Homecare Settings
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Russia
  • 7.5.7. Rest of Europe

8. Asia Pacific Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Dressings
  • 8.1.2. Ointments / Gels
  • 8.1.3. Powders
• 8.2. Market Analysis, Insights and Forecast - By Molecule
  • 8.2.1. Silver
  • 8.2.2. Iodine
  • 8.2.3. Honey
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Wound Type
  • 8.3.1. Chronic Wounds
  • 8.3.2. Acute Wounds
• 8.4. Market Analysis, Insights and Forecast - By End-user
  • 8.4.1. Hospitals
  • 8.4.2. Wound Clinics
  • 8.4.3. Homecare Settings
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. India
  • 8.5.3. Japan
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Dressings
  • 9.1.2. Ointments / Gels
  • 9.1.3. Powders
• 9.2. Market Analysis, Insights and Forecast - By Molecule
  • 9.2.1. Silver
  • 9.2.2. Iodine
  • 9.2.3. Honey
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Wound Type
  • 9.3.1. Chronic Wounds
  • 9.3.2. Acute Wounds
• 9.4. Market Analysis, Insights and Forecast - By End-user
  • 9.4.1. Hospitals
  • 9.4.2. Wound Clinics
  • 9.4.3. Homecare Settings
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle Est & Africa Anti-Biofilm Agents Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Dressings
  • 10.1.2. Ointments / Gels
  • 10.1.3. Powders
• 10.2. Market Analysis, Insights and Forecast - By Molecule
  • 10.2.1. Silver
  • 10.2.2. Iodine
  • 10.2.3. Honey
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Wound Type
  • 10.3.1. Chronic Wounds
  • 10.3.2. Acute Wounds
• 10.4. Market Analysis, Insights and Forecast - By End-user
  • 10.4.1. Hospitals
  • 10.4.2. Wound Clinics
  • 10.4.3. Homecare Settings
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Convatec Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Smith+Nephew
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Coloplast A/S
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Solventum
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Molnlycke AB
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. URGO MEDICAL
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Imbed Biosciences
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)